Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection

NCT01822522 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01822522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2013
Completion date
May 12, 2021
Enrollment
36 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, hiv infection, metastatic malignant solid neoplasm, recurrent malignant solid neoplasm, unresectable solid neoplasm